According to reports, the US FDA has terminated the drug accelerated review program.

Glonghui, November 12｜According to Reuters, the U.S. Food and Drug Administration (FDA) has terminated a drug fast-track review program that was scheduled to launch in June 2025. FDA leadership has informed relevant parties that the National Voucher Program will no longer proceed, although applications are still being accepted. After companies submit applications, the applications will not actually move forward in the review process. Emily Hilliard, spokesperson for the U.S. Department of Health and Human Services, stated that the pilot program is ongoing, and that the FDA is reviewing feedback received at a public hearing in June to improve the framework of the program.